PRKAG2变异型心脏糖原贮积病的临床特征与自然史
本研究回顾性分析了欧洲27个中心90例PRKAG2变异携带者的临床、心电图和超声心动图数据,中位随访6年。结果显示该病为进行性心肌病,表现为高房颤、传导阻滞、心衰和致命性心律失常发生率,典型预激和重度左室肥厚并非普遍存在。
要点
- PRKAG2综合征是进行性心肌病,房颤、传导疾病、心衰和致命性心律失常发生率高。
- 典型预激和重度左室肥厚并非所有患者均存在,诊断需警惕年轻左室肥厚者出现房颤或需起搏器。
- 随访期间21%需新植起搏器,29%发生房颤,14%因心衰入院,8%发生心脏性猝死或等同事件。
核心结论
- PRKAG2综合征是一种进行性心肌病,以高房颤、传导疾病、晚期心衰和危及生命的心律失常为特征。
- 典型预激和重度左室肥厚并非普遍存在,对于年轻左室肥厚患者出现房颤或需永久起搏器时应考虑该诊断。
研究设计与样本
- 回顾性多中心欧洲队列研究,纳入27个中心的90例PRKAG2变异携带者(53%男性,中位年龄33岁,IQR 15-50岁)。
- 收集临床、心电图和超声心动图数据,中位随访6年(IQR 2.3-13.9年)。
主要发现
- 基线时93%患者NYHA心功能I或II级,最大左室壁厚度18±8 mm,左室射血分数61±12%。
- 随访期间71%出现左室肥厚,29%发生房颤,21%需新植起搏器(中位年龄37岁,IQR 29-48岁),14%因心衰入院,8%发生心脏性猝死或等同事件,4%需心脏移植,13%死亡。
临床怎么用
- 对年轻左室肥厚患者,若出现房颤或需永久起搏器,应怀疑PRKAG2综合征并进行基因检测。
- 管理需关注房颤、传导阻滞、心衰和致命性心律失常,必要时起搏器植入和心衰治疗。
局限性
- 回顾性研究设计,可能存在选择偏倚和信息偏倚。
- 样本量有限(90例),随访时间中位6年,可能低估长期并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PRKAG2 gene variants cause a syndrome characterized by cardiomyopathy, conduction disease, and ventricular pre-excitation. Only a small number of cases have been reported to date, and the natural history of the disease is poorly understood. OBJECTIVES: The aim of this study was to describe phenotype and natural history of PRKAG2 variants in a large multicenter European cohort. METHODS: Clinical, electrocardiographic, and echocardiographic data from 90 subjects with PRKAG2 variants (53% men; median age 33 years; interquartile range [IQR]: 15 to 50 years) recruited from 27 centers were retrospectively studied. RESULTS: At first evaluation, 93% of patients were in New York Heart Association functional class I or II. Maximum left ventricular wall thickness was 18 ± 8 mm, and left ventricular ejection fraction was 61 ± 12%. Left ventricular hypertrophy (LVH) was present in 60 subjects (67%) at baseline. Thirty patients (33%) had ventricular pre-excitation or had undergone accessory pathway ablation; 17 (19%) had pacemakers (median age at implantation 36 years; IQR: 27 to 46 years), and 16 (18%) had atrial fibrillation (median age 43 years; IQR: 31 to 54 years). After a median follow-up period of 6 years (IQR: 2.3 to 13.9 years), 71% of subjects had LVH, 29% had AF, 21% required de novo pacemakers (median age at implantation 37 years; IQR: 29 to 48 years), 14% required admission for heart failure, 8% experienced sudden cardiac death or equivalent, 4% required heart transplantation, and 13% died. CONCLUSIONS: PRKAG2 syndrome is a progressive cardiomyopathy characterized by high rates of atrial fibrillation, conduction disease, advanced heart failure, and life-threatening arrhythmias. Classical features of pre-excitation and severe LVH are not uniformly present, and diagnosis should be considered in patients with LVH who develop atrial fibrillation or require permanent pacemakers at a young age.
引用
- Lopez-Sainz A, Dominguez F, Lopes LR, et al. Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. J Am Coll Cardiol. 2020. PMID: 32646569. doi:10.1016/j.jacc.2020.05.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。